Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

From NAFLD to NASH: determining disease progression and regression rates

Authors: Noureddin and Wong
Published in Clinical Gastroenterology and Hepatology (May 2023)
The spectrum of non-alcoholic fatty liver disease (NAFLD) is divisible into three stages: 1) NAFL, 2) non-alcoholic steatohepatitis (NASH), NAFLD’s progressive and inflammatory subtype, and 3) NAFLD or NASH with fibrosis, whose stages range from F0-4.
Read More

Phospholipid depletion and NAFLD pathophysiology: findings from lipidomics

Authors: Mocciaro G, Allison M, Jenkins B et al.
Published in Molecular Metabolism (April 2023)
Along with its association with metabolic syndrome, NAFLD is closely linked with mixed dyslipidaemia (reduced high-density lipoprotein cholesterol (HDL-C) and increased very low-density lipoprotein triglycerides (VLDL-TG)).
Read More

Noninvasive tests for NAFLD: where are we now?

Authors: Alnimer L and Noureddin M
Published in Clinical and Molecular Hepatology (April 2023)
Up to 30% of patients with non-alcoholic fatty liver disease (NAFLD) progress to non-alcoholic steatohepatitis (NASH), significantly increasing their risk of fibrosis and associated adverse outcomes. As such, ensuring the early identification of NAFLD and NASH in at-risk patients is a clinical priority.
Read More

Cardiovascular disease in MAFLD versus NAFLD: a review

Authors: Kang MK, Lee YR, Jang SY et al
Published in Hepatol Int (April 2023)
Changing the terminology from NAFLD, non-alcoholic fatty liver disease, to MAFLD, metabolic dysfunction-associated fatty liver disease, has been an ongoing debate. MAFLD is based upon an individual having hepatic steatosis, as well as either type 2 diabetes mellitus, obesity (or being overweight) or if at a normal weight, two or more metabolic risk abnormalities.
Read More

NASHmap: a new non-invasive tool for NASH identification?

Authors: Schattenberg JM, Balp MM, Reinhart B et al.
Published in Scientific Reports (April 2023)
NASHmap, a non-invasive machine learning model, is revolutionizing NASH identification. Utilizing 14 clinical variables, it offers a promising alternative to invasive liver biopsies. With an 81% positive predictive value, NASHmap can potentially improve clinical practice and specialist referrals for high-risk patients.
Read More

Proteo-Transcriptomics for at-Risk NASH: the Future of Non-Invasive Risk Assessments?

Authors: Ajmera V
Published in Nature Metabolism (April 2023)
Proteo-transcriptomic analyses offer a promising approach for precise NASH risk assessment. A predictive model based on protein levels and clinical variables demonstrates 79% accuracy. This innovative method holds potential for developing blood-based diagnostic tools. Further testing in diverse populations is necessary to validate its efficacy.
Read More

The “Perfect” NASH Biomarker: an Unrealistic Pursuit?

Authors: Sebastiani G
Published in Lancet Gastroenterol Hepatol 2023
Seeking the perfect NASH biomarker may be unrealistic; versatility is key. A diverse biomarker pool adapts to varied clinical contexts and settings. FIB-4, a cost-effective marker, can be supplemented by complex multimarkers for NASH therapeutic trials. Embracing diagnostic imperfections is crucial for flexible biomarker algorithms.
Read More

Cardiovascular Risk in Patients with NAFLD and Inflammatory Bowel Diseases

Authors: Kablawi D, Aljohani F, Palumbo CS et al.
Published in Crohns Colitis 360 2023
NAFLD's prevalence in IBD patients raises concerns for cardiovascular risk. The study found doubled atherosclerotic cardiovascular disease risk in IBD patients with NAFLD. Transient elastography may predict cardiovascular risk in IBD patients. Targeted risk assessments are crucial for IBD patients with NAFLD.
Read More

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES